Bone marrow transplantation (BMT) and peripheral blood stem cell transplantation (PBSCT) are modern therapy options which are frequently used in hematologic diseases, ie leukemia. Both offer a chance for patients in whom other therapies, ie chemotherapy have failed. Modern, potent immunosuppressive drugs have improved prognosis after BMT/PBSCT by preventing graft-versus-host disease (GVHD). However, infectious complications due to immunosuppression are often seen.
Respiratory failure is an important cause of death in patients undergoing BMT. 1 Pulmonary complications are seen in almost 50% of all patients after BMT/PBSCT. Therefore investigation and understanding of pathophysiological processes of underlying infection, immunologic or toxic injury of the lungs after BMT/PBSCT is very important. Bronchoalveolar lavage (BAL) provides an easy way to obtain cells from the alveolar spaces without need of more invasive and dangerous procedure like bronchial biopsy. Nevertheless, until now BAL has mainly been used to identify pathogens, ie cytomegalovirus (CMV).
2-5 BAL cytology after BMT/PBSCT has not been studied extensively and information about the presence of pro-and antiinflammatory cytokines in this compartment is sparse. [6] [7] [8] [9] Previous studies have investigated cytokine patterns in serum and peripheral blood cells after BMT/PBSCT in case of infection and GVHD. [10] [11] [12] GVHD is characterized by activation of Th1 subsets of CD4 + helper cells resulting in interleukin-2 production. Tissue injury results in invasion of bacteria and lipopolysaccharide production that stimulates macrophages to produce proinflammatory cytokines, ie tumor necrosis factor-␣ (TNF␣). 13, 14 Recent studies also showed an increase of interleukin-18 (IL-18) serum protein levels in GVHD. 15, 16 In this study expression of TNF␣ and IL-18 as examples of proinflammatory cytokines and IL-10 as an example of an anti-inflammatory cytokine involved in numerous immunologic and infectious diseases 17 was measured in BAL cells of patients with pulmonary complications after BMT or PBSCT. To our knowledge this is the first report on cytokine expression in human BAL cells in case of pulmonary complications after BMT/PBSCT.
Bone Marrow Transplantation

Materials and methods
Patients and controls
From January 1998 to December 2000 in the University Hospital Eppendorf, 48 patients received BAL for pulmonary complications following BMT or PBSCT. Twenty patients were transplanted for leukemia and investigated further. The group included 17 male and three female subjects (mean age 41.3 Ϯ 9.5 years, mean Ϯ s.d.). It was divided into two subgroups according to the type of complication (infection or immunologic injury). Fourteen patients had infectious pneumonia after BMT/PBSCT. Six patients had immunologic injury of the lungs after BMT/PBSCT (three idiopathic pneumonia syndrome, IPS; three bronchiolitis obliterans, BO). Pulmonary infections were diagnosed by clinical and radiological signs in combination with inflammatory markers in serum (elevated C-reactive protein). BO was diagnosed by presence of airflow obstruction in the lung function testing and histopathological findings. IPS was diagnosed by exclusion of other causes. All patients with infectious pneumonia were treated with antibiotics. Three patients of the IPS/BO group received antibiotics. Twelve patients were treated with glucocorticosteroids and 14 with cyclosporine A. Table 1 summarizes the characteristics of both patient groups.
Eleven healthy volunteers served as a control group (seven male, five female, mean age 25.9 Ϯ 5.9 years).
Bronchoalveolar lavage
After informed consent had been obtained, all patients and control individuals underwent fiberoptic bronchoscopy. BAL was carried out by instilling 160 ml of sterile 0.9% saline solution, in 20 ml aliquots, into the middle lobe and by withdrawing the fluid immediately. l volume of isopropanol was added to each tube and RNA was precipitated by light mixing. After incubating at room temperature for 10 min samples were centrifuged for 10 min at 4°C at 12 000 r.p.m. The supernatant was removed and the RNA-containing gel-like pellet at the bottom-side of the tube was washed with 75% ethanol. The sample was vortexed and centrifuged for 5 min at 4°C at 7500 r.p.m. Then the supernatant was removed and the RNA pellet was partially dried. After redissolving the RNA pellet in DEPCtreated water the RNA was denatured for 10 min at 60°C. The concentration of RNA was adjusted to 0.15 g/l per sample. Samples were stored at Ϫ20°C until further preparation.
RT-PCR
RNA was reverse-transcribed using 2 l 25 mm 18,19 ␤-Actin served as control. The human ␤-actin primers were 5Ј-GTG GGG CGC CCC AGG CAC CA-3Ј for the upstream primer and 5pm-CTC CTT AAT GTC ACG CAC GAT TTC-3Ј for the downstream primer; IL-18 utilized 5Ј-GCT TGA ATC TAA ATT ATC AGT C-3Ј for the upstream primer and 5Ј-GAA GAT TCA AAT TGC ATC TTA T-3Ј for the downstream primer. TNF␣ primers were 5Ј-CAG AGG GAA GAG TTC CCC AG-3Ј for the upstream primer and 5Ј-CCT TGG TCT GGT AGG AGA CG-3Ј for the downstream primer; IL-10 primers utilized 5Ј-ATG CCC CAA GCT GAG AAC CAA GAC CCA-3Ј for the upstream primer and 5Ј-TCT CAA GGG GCT GGG TCA GCT ATC CCA-3Ј for the downstream primer. PCR amplification for ␤-actin was performed for 36 cycles (1 min at 94°C, 1 min at 60°C, 40 s at 72°C), for 35 cycles (1 min at 72°C, 1 min at 90°C, 1 min at 55°C) for IL-18, for 40 cycles (1 min at 94°C, 1 min at 60°C, 40 s at 72°C) for TNF␣ and for 35 cycles (1 min at 94°C, 1 min at 59°C, 40 s at 72°C) for IL-10.
Identification of PCR products
PCR products were analyzed by electrophoresis on a 2% agarose gel containing ethidium bromide and visualized by UV light. The sizes of PCR products were compared with the expected PCR product length and molecular weight markers (Boehringer, Mannheim, Germany).
Densitometric and semi-quantitative PCR analysis
Densitometric analysis was performed by the Eagle Eye II Still Video System (Stratagene, La Jolla, CA, USA). All cytokine signals produced by RT-PCR were within the linear range of the assay. The expression was standardized to that of ␤-actin expression from the same reverse-transcribed cytokine (IL-18, TNF␣, IL-10) mRNA sample. Ratios of IL-18:␤-actin, TNF␣:␤-actin and IL-10:␤-actin were calculated for semiquantitative RNA expression analysis as previously described. 20 
Statistics
Patient groups and control group were compared using a Mann-Whitney test. Results are expressed as mean Ϯ s.e.m.. A P value <0.05 was considered significant. Cox's regression model was used to determine prediction of survival by TNF␣, IL-10 or IL-18. Table 2 summarizes the results of BAL differential cell counts and microbiological findings in both patient groups. Only one patient in the IPS/BO group had aspergillus in BAL but histopathology proved the diagnosis of BO in this patient.
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Results
BAL differential cell counts and microbiology
Expression of TNF␣ mRNA
BAL cells of all patients expressed TNF␣ mRNA. In the control group TNF␣ expression could only be detected in BAL cells from six of 11 tested individuals. TNF␣ expression was significantly increased in patients with infectious pneumonia (0.40 Ϯ 0.07) and in patients with IPS/BO (0.39 Ϯ 0.09) in comparison to control subjects (0.15 Ϯ 0.05, P <0.05, Figures 1a and 2a , Table 3 ). There was no significant difference between the patient groups (P >0.05).
Expression of IL-10 mRNA
IL-10 mRNA expression could be shown in BAL cells of seven patients with infectious pneumonia and in two patients with IPS/BO. In the control group IL-10 expression could only be detected in BAL cells of two volunteers. The mean value of IL-10:␤-actin ratios was significantly increased in patients with infectious pneumonia (0.15 Ϯ 0.06) compared to control subjects (0.01 Ϯ 0.01, P <0.05, Figures 1b and 2b, Table 3 ). In contrast, no significant difference could be observed between patients with IPS/BO (0.05 Ϯ 0.04) and control subjects (P >0.05). The difference in IL-10 expression between both patient groups just failed to reach statistical signficance (P ϭ 0.07).
Expression of IL-18 mRNA
BAL cells of all patients and of all tested control individuals (n ϭ 8) expressed IL-18 mRNA. IL-18 expression was significantly decreased in patients with infectious pneumonia (1.47 Ϯ 0.24) and in patients with IPS/BO (1.79 Ϯ 0.63) in comparison to control subjects (4.29 Ϯ 0.77, P <0.05, Figures 1c and 2c, Table 3 ). There was no significant difference between either patient groups (P >0.05). 
Analysis of TNF␣, IL-10 and IL-18 as predictors of survival
TNF␣, IL-10 and IL-18 mRNA expression in BAL cells was analyzed as a possible predictor of prognosis for the whole patient group (n ϭ 20). IL-10 and IL-18 were not suitable as predictors concerning survival. However, increased mRNA expression of TNF␣ was significantly associated with a poor prognosis (P < 0.05). 
489
Discussion
Pulmonary complications pose a major clinical problem after successfull BMT/PBSCT. 1 Previous studies have shown that serum levels of TNF␣, IL-10 and IL-18 are changed in cases of infection or GVHD after BMT. Elevated TNF␣ serum protein levels precede major complications of BMT and TNF␣ is increased in serum in cases of GVHD.
11, 12 Liem et al 10 found increased IL-10 serum protein concentrations during both infections and GVHD. Recent studies reported elevated IL-18 serum protein levels in patients with GVHD. 15, 16 However, information about cyotokine levels in the pulmonary compartment after BMT/PBSCT is small. Local production of interleukin-2 and interferon-␥ which could be measured in BAL from BMT recipients with CMV pneumonia did not correlate with natural killer cell activity. 8 Clark et al 9 demonstrated proinflammatory cytokine activation in IPS following BMT. In the same study patients without IPS had normal levels for interleukin-1, interleukin-2, interleukin-6 and TNF␣ in BAL but these molecules were elevated in patients with IPS. However, Rawbottom et al 12 proposed that measurement of cytoplasmic cytokines (in peripheral blood cells) might be better markers for acute GVHD than monitoring (serum) cytokine levels. Another study by Sparrelid et al 21 investigated lung tissue biopsies of BMT patients with interstitial pneumonitis. Herein immunohistochemical analysis revealed a Th2 cytokine pattern with increased numbers IL-4 and IL-10 producing cells in patients with fatal outcome.
In the present study we were able to show increased expression of TNF␣ and IL-10 in BAL cells of patients with pulmonary complications after BMT/PBSCT whereas IL-18 expression was decreased. To our knowledge, this is the first study on mRNA expression of these cytokines in BAL cells of patients with pulmonary complications following BMT or PBSCT.
We divided the patient group into two subgroups (infectious pneumonia and IPS/BO) in order to better investigate cytokine expression in infectious and in non-infectious lung injury. IPS and acute BO are both thought to be mediated by a Th1 predominated immune response. 22, 23 The time after BMT was only 7 months (median) in the patient group with IPS/BO reflecting acute, Th1 predominated immunologic processes.
In cases of infection, BAL differential cell counts showed an increase in neutrophils whereas non-infectious injury led to lymphocytosis. These data agree with previous reports but it has to be taken into account that in a study by de la Camara et al 7 BAL of BMT patients without lung
Bone Marrow Transplantation complications also showed a marked increase in neutrophils. Therefore BAL cytology after BMT/PBSCT must be interpreted with care. Alveolar macrophage counts were slightly decreased in patients suggesting that alveolar macrophages which are derived from the grafted bone marrow 24 play an important role in pulmonary defense after BMT/PBSCT. Milburn et al 25 showed that alveolar macrophages in BMT recipients with pneumonitis had increased proportions of cells with a monocyte phenotype (CD14 + , UCHM1) and reduced proportions of cells positive for DR antigen (class II major histocompatibility complex). These findings indicated a severe dysregulation of local immunoreaction which might, in part, be responsible for the high incidence of pulmonary infections. 25 Since BAL cytology seems to be of limited value after BMT/PBSCT, cytokine patterns might shed some light on pathophysiological processes in pulmonary complications. In the present study TNF␣ mRNA expression was significantly increased in both patient groups in comparison to healthy controls. This is in agreement with previous studies which demonstrated elevated TNF␣ in both infectious complications and in GVHD. 11, 12 IL-10 mRNA expression was also elevated in both patient groups. However, a significant increase could only be found in patients with infectious pneumonia compared to control subjects. IL-10 might probably play a role as a counter-regulating mediator in lung infections after BMT in order to prevent harmful effects of TNF␣ overexpression. In contrast there was no significant increase of IL-10 in patients with IPS/BO. This agrees with previous data showing that IPS and acute BO are mediated by a Th1 predominated immune response in the early stage. 22, 23 Although a raise of IL-10 in serum caused by the transplantation regimen itself has been described, 10 this could not be observed in the BAL cells.
IL-18 expression in BAL cells of all patients were significantly lower than in healthy volunteers which is in contrast to the studies of Nakamura et al 15 and Fujimori et al, 16 who analyzed IL-18 serum protein levels in patients with GVHD exclusively. Zecchina et al 26 reported an upregulation of both IL-18 and its inhibitor IL-18 binding protein in GVHD. In an animal model blockade of IL-18 accelerated acute GVHD-related mortality whereas administration of IL-18 resulted in significantly improved survival. IL-18 induced enhanced Fas-mediated apoptosis of donor T cells early after BMT. 27 These studies indicate that IL-18 might also have a protective effect against GVHD. Therefore decreased IL-18 expression in the lungs as found in our study might lead to development of pulmonary GVHD.
IL-18 has been also reported to have immunoregulatory functions in defense against pathogens. Bacteria such as streptococcus pyogenes have been shown to induce IL-18 secretion 28 . Therefore decreased IL-18 might promote infection in patients after BMT/PBSCT. It is tempting to speculate that local immune defense is compromised in BMT/PBSCT recipients probably by the immunosuppressive therapy. Another possible explanation might be consumption of IL-18 in the lung compartment especially in infectious complications.
Although analysis of various factors including age, sex, diagnosis, medication, pathogens and HLA identity between host and donor was performed, no influence of TNF␣, IL-10 or IL-18 could be demonstrated. Analysis of the three cytokines as possible predictors of survival revealed that high TNF␣ mRNA expression in BAL cells was associated with a poor prognosis.
In conclusion, in this preliminary study, elevation of TNF␣ and IL-10 and reduction of IL-18 in patients with pulmonary complications after BMT/PBSCT in comparison to normal individuals could be found indicating compromised local defense. We did not examine BMT/PBSCT patients without complications but previous studies showed that BAL cytokine levels did not differ between patients without complications and healthy volunteers. 9 Although we only analyzed a small group of patients our results indicate that BAL can be used to examine cytokine expression and regulation in the lung compartment after BMT/PBSCT. BAL has the great advantage over bronchial biopsies that it can be performed even in patients with impaired blood coagulation. However, further studies with serial lavages are warranted to determine the patterns of pro-and antiinflammatory cytokines in the lungs before and after BMT and PBSCT as well in patients with and without complications. This would probably help to identify those patients with an elevated risk for complications and indicate a close monitoring of this population.
